AbbVie 2013 Annual Report Download - page 136
Download and view the complete annual report
Please find page 136 of the 2013 AbbVie annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.-
1 -
2
-
3
-
4
-
5
-
6
-
7
-
8
-
9
-
10
-
11
-
12
-
13
-
14
-
15
-
16
-
17
-
18
-
19
-
20
-
21
-
22
-
23
-
24
-
25
-
26
-
27
-
28
-
29
-
30
-
31
-
32
-
33
-
34
-
35
-
36
-
37
-
38
-
39
-
40
-
41
-
42
-
43
-
44
-
45
-
46
-
47
-
48
-
49
-
50
-
51
-
52
-
53
-
54
-
55
-
56
-
57
-
58
-
59
-
60
-
61
-
62
-
63
-
64
-
65
-
66
-
67
-
68
-
69
-
70
-
71
-
72
-
73
-
74
-
75
-
76
-
77
-
78
-
79
-
80
-
81
-
82
-
83
-
84
-
85
-
86
-
87
-
88
-
89
-
90
-
91
-
92
-
93
-
94
-
95
-
96
-
97
-
98
-
99
-
100
-
101
-
102
-
103
-
104
-
105
-
106
-
107
-
108
-
109
-
110
-
111
-
112
-
113
-
114
-
115
-
116
-
117
-
118
-
119
-
120
-
121
-
122
-
123
-
124
-
125
-
126 -
127 -
128 -
129 -
130 -
131 -
132 -
133 -
134 -
135 -
136 -
137 -
138 -
139 -
140 -
141 -
142 -
143 -
144 -
145 -
146 -
147
-
148
-
149
-
150
-
151
-
152
-
153
-
154
-
155
-
156
-
157
-
158
-
159
-
160
-
161
-
162
-
163
-
164
-
165
-
166
-
167
-
168
-
169
-
170
-
171
-
172
-
173
-
174
-
175
-
176
 |
 |
will receive one common share for each restricted stock unit outstanding under the Incentive Stock
Program.
The following AbbVie restricted stock units were outstanding as of December 31, 2013: R. Alpern,
11,094; R. Austin, 18,757; W. Burnside, 2,535; E. Liddy, 6,521; E. Rapp, 2,535; R. Roberts, 2,535;
G. Tilton, 14,741; F. Waddell, 2,535. These numbers include, where applicable, AbbVie restricted
stock units issued when AbbVie separated from Abbott Laboratories on January 1, 2013. The
AbbVie awards resulted from an anti-dilution adjustment in accordance with terms of the Abbott
awards designed to preserve the value of the Abbott awards, so the January 1, 2013 awards are not
included in the Director Compensation table. When AbbVie separated from Abbott, the directors
and other holders of Abbott restricted stock units generally retained those awards and received
restricted stock units of AbbVie in an amount that reflected the distribution to Abbott
shareholders. Such awards are subject to substantially the same terms, vesting conditions and other
restrictions that applied to the original Abbott awards immediately before the distribution.
(3) No AbbVie stock options were outstanding as of December 31, 2013.
(4) The totals in this column include reportable interest credited under the AbbVie Non-Employee
Directors’ Fee Plan during 2013.
(5) Charitable contributions made by AbbVie’s non-employee directors are eligible for a matching
contribution (up to $25,000 annually). During 2013, AbbVie made charitable matching
contributions on behalf of the following AbbVie directors: W. Burnside, $12,500; E. Rapp, $25,000;
R. Roberts, $25,000; G. Tilton, $25,000; F. Waddell, $25,000. This column also includes
reimbursement for certain taxes.
13